Study suggests inhaled technosphere insulin could be considered as an option for adults with type 1 diabetes

A study in the journal Diabetes Technology & Therapeutics (DTT) concludes that inhaled technosphere insulin (TI-Afrezza) should be considered as an option for individuals with type 1 diabetes who want an alternative to using an insulin pump or multiple daily injections (MDI) for insulin delivery.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup